Citadel Advisors
QTTB icon

Citadel Advisors’s Q32 Bio QTTB Stock Holding History

Citadel Advisors’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,700
Closed -$19.6K – 15752
2024
Q4 		$19.6K Buy
+5,700
New +$180K ﹤0.01% 13192
2024
Q1 		– Sell
-6
Closed -$61 – 15569
2023
Q4 		$61 Hold
6
– – ﹤0.01% 14143
2023
Q3 		$117 Sell
6
-66
-92% -$1.35K ﹤0.01% 14160
2023
Q2 		$1.15K Sell
72
-106
-60% -$1.9K ﹤0.01% 13977
2023
Q1 		$3.3K Buy
178
+145
+439% +$3.61K ﹤0.01% 14052
2022
Q4 		$756 Buy
+33
New +$876 ﹤0.01% 14588
2022
Q3 		– Sell
-983
Closed -$35K – 13763
2022
Q2 		$35K Sell
983
-1,067
-52% -$36.4K ﹤0.01% 12146
2022
Q1 		$112K Buy
2,050
+450
+28% +$27.9K ﹤0.01% 12169
2021
Q4 		$105K Buy
1,600
+44
+3% +$4.27K ﹤0.01% 12672
2021
Q3 		$220K Sell
1,556
-1,000
-39% -$127K ﹤0.01% 11789
2021
Q2 		$334K Buy
2,556
+528
+26% +$65.9K ﹤0.01% 11010
2021
Q1 		$343K Buy
2,028
+161
+9% +$33.9K ﹤0.01% 10532
2020
Q4 		$379K Sell
1,867
-50
-3% -$9.66K ﹤0.01% 8664
2020
Q3 		$369K Buy
+1,917
New +$430K ﹤0.01% 7791

Other funds holding QTTB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors's QTTB Position: Q1 2026 in Review

Citadel Advisors reduced its Q32 Bio (QTTB) stake by 66% in Q1 2026, selling an estimated $144K and leaving 15,481 shares worth $99.4K. The position accounts for ﹤0.01% of the portfolio, ranked #12029.

Citadel Advisors first reported a position in QTTB in Q1 2018 and has held it in 26 quarters since. The position peaked at $13.3M in Q3 2019. 54 funds tracked by Wall St. Rank hold QTTB as of Q1 2026.

  • Citadel Advisors held 15,481 shares of Q32 Bio worth $99.4K as of Q1 2026.
  • Citadel Advisors sold 30,247 Q32 Bio shares in Q1 2026, an estimated $144K.
  • Q32 Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12029 holding.
  • Citadel Advisors first reported a position in Q32 Bio in Q1 2018 and has held it in 26 quarters since.
  • Citadel Advisors's Q32 Bio position peaked at $13.3M in Q3 2019.
  • 54 funds tracked by Wall St. Rank held Q32 Bio as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.